Navigation Links
NPS Pharmaceuticals to Present at BIO CEO & Investor Conference
Date:2/4/2008

BEDMINSTER, N.J., Feb. 4 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that Francois Nader, M.D., executive vice president and chief operating officer, is scheduled to present at the 10th Annual BIO CEO and Investor Conference in New York on Monday, February 11, 2008 at 1:15 p.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the NPS website, http://www.npsp.com.

About NPS Pharmaceuticals

NPS Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The Company has drug candidates in various stages of clinical development. Additional information is available on the NPS website, http://www.npsp.com.


'/>"/>
SOURCE NPS Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , ... April 26, 2017 , ... ... to improve the profitability of ready-to-drink, high-protein beverages by helping beverage manufacturers more ... to dairy proteins, providing direct cost savings as well as more stable pricing ...
(Date:4/25/2017)... ... 25, 2017 , ... ProRehab Physical Therapy (PRPT) ... physical therapy provider for Derby City CrossFit, effective immediately. , In addition to ... and effectively as possible, ProRehab’s sports physical therapists will work with athletes to ...
(Date:4/25/2017)... ... April 25, 2017 , ... The doctors at Wall Centre Dental are now ... fear and require sedation to receive dental care. The doctors offer three treatment options ... hygienic cleanings to oral surgery, at their dental office in Vancouver. Wall Centre Dental ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers of America ... a reputable physician in their area, announces the launch of a new and proprietary ... who are looking for reputable physicians to help them with back or neck pain ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in South Florida ... report in the May issue of Consumer Reports focused on heart health. , ... achieved during and after coronary bypass and aortic valve replacement procedures. , Consumer ...
Breaking Medicine News(10 mins):
(Date:4/21/2017)... -- Halo Labs announces the launch of a novel ... the Horizon at PEGS 2017 in Boston ... sub visible particulate matter in biopharmaceutical samples to enable ... as candidate selection and pre-formulation. Halo Labs ... Elion Labs for system validation. "We are ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, ... their offering. ... pharmacogenomics market was valued at US$ 7,167.6 Mn in 2015, ... expanding at a CAGR of 5.6% from 2016 to 2024. ...
Breaking Medicine Technology: